Page 7 - Agonist News Today

The world's first IVF baby, Louise Brown born in England in 1978, was conceived from a naturally developing follicle in her mother's ovary.

AX-8 reduces cough frequency and improves patient-reported outcomes in patients with chronic cough Axalbion, a clinical-stage biopharmaceutical company focused on developing novel medicines to treat

Sanjay Keswani, MBBS, FRCP to join company as Chief Medical Officer bringing extensive experience in drug development and life sciences leadershipLynne Murray, Ph.D., MBA appointed as Chief Scientific

The brain has a natural protective mechanism against Alzheimer disease, and researchers have discovered that gene variants associated with the risk of develop

The brain has a natural protective mechanism against Alzheimer disease, and researchers have discovered that gene variants associated with the risk of develop

BT7480 is the Company's Fourth Product Candidate to Enter the Clinic in the Past Four Years This is Bicycle's First Immuno-oncology Asset to Enter the Clinic Bicycle Therapeutics plc (NASDAQ: BCYC)

TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Limited (TAK) said that a safety signal has emerged in Phase 2 studies of TAK-994, an investigational oral orexin agonist. As an immediate precautionary

Patent protection in U.S. runs through 2037 CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 10, 2021(NASDAQ: FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company dedicated

F-star Therapeutics, Inc.: Study Published in Nature Shows F-Stars STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy SB 11285 is a Second Generation STING Agonist Delivered Intravenously CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 19, 2021. The study entitled "STING enhances cell death through regulation of reactive oxygen species and DNA damage" demonstrates that systemic administration of a STING agonist in combination with radiation in a preclinical model en...

Cleveland BioLabs, Inc: Genome Protection Announces Publication of the Next Generation Deimmunized TLR5 Agonist, GP532 The substantially improved pharmacological profile of GP532 opens new opportunities for broader therapeutic applications of this class of pharmaceuticals BUFFALO, NY / ACCESSWIRE / April 14, 2021 / Genome Protection, Inc. (GPI), a joint venture between Cleveland BioLabs, Inc. (NASDAQ:CBLI) and Everon BioSciences, LLC, an innovative biopharmaceutical company focused on developin...